日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

BMS-986299(一种 NLRP3 激动剂)单药治疗以及与纳武利尤单抗和伊匹木单抗联合治疗晚期实体瘤患者的 I 期研究

Nelson, Blessie E; O'Brien, Shaun; Sheth, Rahul A; Hong, David S; Naing, Aung; Zhang, Xiaoping; Xu, Amy; Hamuro, Lora; Suryawanshi, Rasika; McKinley, Derrick; Novosiadly, Ruslan D; Piha-Paul, Sarina A

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

帕博利珠单抗联合瘤内注射诺维梭菌-NT治疗晚期实体瘤患者的Ib期研究。

Nelson Blessie Elizabeth, Janku Filip, Fu Siqing, Dumbrava Ecaterina E, Hong David S, Karp Daniel D, Naing Aung, Rodon Jordi, Tsimberidou Apostolia M, Murthy Ravi, Sheth Rahul A, Amaria Rodabe N, Conley Anthony P, Damodaran Senthil, Raghav Kanwal P S, Carapanceanu Nicoleta, Singh Mahendra Pal, Carapanceanu Valentin, Pezeshki Abdulmohammad, Leontovich Alexey A, Kreider Brent L, Tung David, Varterasian Mary, Khazaie Khashayarsha, Piha-Paul Sarina A

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

RAF抑制剂在BRAF异常泛癌中的再次挑战治疗:RE-RAFFLE研究

Nelson, Blessie Elizabeth; Roszik, Jason; Ahmed, Jibran; Barretto, Carmelia Maria Noia; Nardo, Mirella; Campbell, Erick; Johnson, Amber M; Piha-Paul, Sarina A; Oliva, Isabella C Glitza; Weathers, Shiao-Pei; Cabanillas, Maria; Javle, Milind; Meric-Bernstam, Funda; Subbiah, Vivek

Decentralized Clinical Trials in Early Drug Development-A Framework Proposal

早期药物研发中的分散式临床试验——框架提案

Silva, Diogo J; Nelson, Blessie Elizabeth; Rodon, Jordi

The abscopal effect in patients with cancer receiving immunotherapy

接受免疫疗法的癌症患者的远隔效应

Nelson, Blessie Elizabeth; Adashek, Jacob J; Lin, Steven H; Subbiah, Vivek

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

针对RET基因改变癌症患者,采用选择性RET抑制剂减轻不良事件的策略

Nardo, Mirella; Gouda, Mohamed A; Nelson, Blessie E; Barreto, Carmelia M N; Slade, J Hoyt; Poullard, Anna; Zafereo, Mark; Hu, Mimi I; Cabanillas, Maria E; Subbiah, Vivek

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications

来自 AACR GENIE 数据库的肿瘤非特异性精准医学:临床意义

Gouda, Mohamed A; Nelson, Blessie E; Buschhorn, Lars; Wahida, Adam; Subbiah, Vivek

BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

BRAF v600E突变型癌症接受维莫非尼单药治疗或联合依维莫司、索拉非尼或克唑替尼治疗,或联合紫杉醇和卡铂治疗(VEM-PLUS研究)

Nelson, Blessie Elizabeth; Roszik, Jason; Janku, Filip; Hong, David S; Kato, Shumei; Naing, Aung; Piha-Paul, Sarina; Fu, Siqing; Tsimberidou, Apostolia; Cabanillas, Maria; Busaidy, Naifa Lamki; Javle, Milind; Byers, Lauren Averett; Heymach, John V; Meric-Bernstam, Funda; Subbiah, Vivek

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

在BRAF V600E突变型胶质母细胞瘤中,BRAF/MEK联合抑制可导致组织学转化为胶质肉瘤。

Nelson, Blessie Elizabeth; Reddy, Neha K; Huse, Jason T; Amini, Behrang; Nardo, Mirella; Gouda, Mohamed; Weathers, Shiao-Pei; Subbiah, Vivek

Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers

预测远隔效应:相关肿瘤组织学亚型和生物标志物

Nelson, Blessie Elizabeth; Adashek, Jacob J; Sheth, Aakash Akshay; Subbiah, Vivek